Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 35

1.

Murine atopic dermatitis responds to peroxisome proliferator-activated receptors alpha and beta/delta (but not gamma) and liver X receptor activators.

Hatano Y, Man MQ, Uchida Y, Crumrine D, Mauro TM, Feingold KR, Elias PM, Holleran WM.

J Allergy Clin Immunol. 2010 Jan;125(1):160-9.e1-5. doi: 10.1016/j.jaci.2009.06.049. Epub 2009 Oct 8.

2.

Thematic review series: skin lipids. Peroxisome proliferator-activated receptors and liver X receptors in epidermal biology.

Schmuth M, Jiang YJ, Dubrac S, Elias PM, Feingold KR.

J Lipid Res. 2008 Mar;49(3):499-509. doi: 10.1194/jlr.R800001-JLR200. Epub 2008 Jan 8. Review.

3.

Peroxisome proliferator-activated receptors (PPARs) and the human skin: importance of PPARs in skin physiology and dermatologic diseases.

Sertznig P, Seifert M, Tilgen W, Reichrath J.

Am J Clin Dermatol. 2008;9(1):15-31. Review.

PMID:
18092840
4.

Role of PPAR, LXR, and PXR in epidermal homeostasis and inflammation.

Schmuth M, Moosbrugger-Martinz V, Blunder S, Dubrac S.

Biochim Biophys Acta. 2014 Mar;1841(3):463-73. doi: 10.1016/j.bbalip.2013.11.012. Epub 2013 Dec 3. Review.

PMID:
24315978
5.

Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications--a review.

Grygiel-Górniak B.

Nutr J. 2014 Feb 14;13:17. doi: 10.1186/1475-2891-13-17. Review.

6.

Peroxisome proliferator-activated receptor targets for the treatment of metabolic diseases.

Monsalve FA, Pyarasani RD, Delgado-Lopez F, Moore-Carrasco R.

Mediators Inflamm. 2013;2013:549627. doi: 10.1155/2013/549627. Epub 2013 May 27. Review.

7.

PPARbeta/delta ligands as modulators of the inflammatory response.

Kilgore KS, Billin AN.

Curr Opin Investig Drugs. 2008 May;9(5):463-9. Review.

PMID:
18465655
8.

Peroxisome proliferator-activated receptors (PPARs) in skin health, repair and disease.

Michalik L, Wahli W.

Biochim Biophys Acta. 2007 Aug;1771(8):991-8. Epub 2007 Feb 24. Review.

PMID:
17400022
9.

Peroxisome proliferator-activated receptor (PPAR)β/δ, a possible nexus of PPARα- and PPARγ-dependent molecular pathways in neurodegenerative diseases: Review and novel hypotheses.

Aleshin S, Strokin M, Sergeeva M, Reiser G.

Neurochem Int. 2013 Oct;63(4):322-30. doi: 10.1016/j.neuint.2013.06.012. Epub 2013 Jun 25. Review.

PMID:
23811400
10.

PPAR dual agonists: are they opening Pandora's Box?

Balakumar P, Rose M, Ganti SS, Krishan P, Singh M.

Pharmacol Res. 2007 Aug;56(2):91-8. Epub 2007 Mar 14. Review.

PMID:
17428674
11.

Antihypertensive effects of peroxisome proliferator-activated receptor-β/δ activation.

Toral M, Romero M, Pérez-Vizcaíno F, Duarte J, Jiménez R.

Am J Physiol Heart Circ Physiol. 2017 Feb 1;312(2):H189-H200. doi: 10.1152/ajpheart.00155.2016. Epub 2016 Nov 23. Review.

PMID:
27881385
12.

Peroxisome proliferator-activated receptor (PPAR) beta/delta: a new potential therapeutic target for the treatment of metabolic syndrome.

Coll T, Rodrïguez-Calvo R, Barroso E, Serrano L, Eyre E, Palomer X, Vázquez-Carrera M.

Curr Mol Pharmacol. 2009 Jan;2(1):46-55. Review.

PMID:
20021445
13.

Peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) acts as regulator of metabolism linked to multiple cellular functions.

Wagner KD, Wagner N.

Pharmacol Ther. 2010 Mar;125(3):423-35. doi: 10.1016/j.pharmthera.2009.12.001. Epub 2009 Dec 22. Review.

PMID:
20026355
14.

Hepatic PPARs: their role in liver physiology, fibrosis and treatment.

Zardi EM, Navarini L, Sambataro G, Piccinni P, Sambataro FM, Spina C, Dobrina A.

Curr Med Chem. 2013;20(27):3370-96. Review.

PMID:
23746272
15.

Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.

Touyz RM, Schiffrin EL.

Vascul Pharmacol. 2006 Jul;45(1):19-28. Epub 2006 Jun 16. Review.

PMID:
16782410
16.

The role of PPARβ/δ in the management of metabolic syndrome and its associated cardiovascular complications.

Benetti E, Patel NS, Collino M.

Endocr Metab Immune Disord Drug Targets. 2011 Dec;11(4):273-84. Review.

17.

Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors.

O'Sullivan SE.

Br J Pharmacol. 2007 Nov;152(5):576-82. Epub 2007 Aug 20. Review.

18.

[Pathophysiological relevance of peroxisome proliferators activated receptors (PPAR) to joint diseases - the pro and con of agonists].

Jouzeau JY, Moulin D, Koufany M, Sebillaud S, Bianchi A, Netter P.

J Soc Biol. 2008;202(4):289-312. doi: 10.1051/jbio:2008034. Epub 2008 Dec 19. Review. French.

PMID:
19094928
19.

Liver X receptor and peroxisome proliferator-activated receptor as integrators of lipid homeostasis and immunity.

Kidani Y, Bensinger SJ.

Immunol Rev. 2012 Sep;249(1):72-83. doi: 10.1111/j.1600-065X.2012.01153.x. Review.

20.

Lipid abnormalities and lipid-based repair strategies in atopic dermatitis.

Elias PM.

Biochim Biophys Acta. 2014 Mar;1841(3):323-30. doi: 10.1016/j.bbalip.2013.10.001. Epub 2013 Oct 12. Review.

Supplemental Content

Support Center